Results 101 to 110 of about 30,790 (243)

Meningeal marginal zone B-cell lymphoma: The meningioma trap

European Annals of Otorhinolaryngology, Head and Neck Diseases, 2018
To report a case of marginal zone MALT lymphoma of the temporal dura mater, initially mistaken for temporal meningioma.A 60-year-old immunocompetent woman, followed for more than 10 years for temporal meningioma causing vertigo and mixed hearing loss, presented with cervical lymphadenopathy, revealing marked progression of an intracranial lesion ...
Alexandre, Villeneuve, François, Rubin, Pierre, Bonfils   +2 more
openaire   +2 more sources

Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy

Clinical and Developmental Immunology, 2012
The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin’s lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United ...
Luca Arcaini, Michele Merli, Stefano Volpetti, Sara Rattotti, Manuel Gotti, Francesco Zaja   +5 more
doaj   +1 more source

TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents [PDF]

, 2017
BACKGROUND: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains ...
Amodeo, Rachele, Bove, Maurizio, Cox, Maria Christina, D'Amelio, Raffaele, DI ROSA, Roberta, Lagana', Bruno, Markovic, Milica, PICCHIANTI DIAMANTI, Andrea, Pilozzi, Emanuela, Rosado, Maria Manuela, Salemi, Simonetta, Sorgi, Maria Laura   +11 more
core   +1 more source

Pattern and Clinical Significance of CA19‐9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Carbohydrate antigen 19–9 (CA19‐9) is a cell surface glycoprotein widely used as a diagnostic and prognostic serum marker for monitoring pancreatic cancer. The aim of this study was to evaluate the prevalence and clinical relevance of CA19‐9 expression in human cancer. Methods To comprehensively determine the prevalence and clinical
Nina Schraps, Anne Menz, Florian Viehweger, Seyma Büyücek, David Dum, Ria Schlichter, Andrea Hinsch, Christoph Fraune, Christian Bernreuther, Martina Kluth, Claudia Hube‐Magg, Katharina Möller, Viktor Reiswich, Andreas M. Luebke, Patrick Lebok, Sören Weidemann, Guido Sauter, Maximilian Lennartz, Frank Jacobsen, Till S. Clauditz, Andreas H. Marx, Ronald Simon, Stefan Steurer, Baris Mercanoglu, Nathaniel Melling, Thilo Hackert, Eike Burandt, Natalia Gorbokon, Sarah Minner, Till Krech, Florian Lutz, Morton Freytag   +31 more
wiley   +1 more source

Recurrent localized primary cutaneous marginal-zone B-cell lymphoma

Dermatology Online Journal, 2011
A 36-year-old man with a prior diagnosis of primary cutaneous marginal-zone B cell lymphoma presented with newly-developed, small, erythematous papules and nodules on his upper left arm and pink-to-skin-colored, clustered papules on his left forearm.
Marmon, Shoshana, Chu, Julie, Patel, Rishi, Meehan, Shane, Pomeranz, Miriam Keltz   +4 more
openaire   +4 more sources

Drivers of B-cell lymphoma [PDF]

Around 5000 people in the Netherlands are diagnosed with lymphoma each year. This thesis focused on two types of B-cell-derived lymphomas: marginal zone lymphoma and diffuse large B-cell lymphoma.
Bult, Johanna
core   +1 more source

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

Haematologica, 2012
The genetics and pathogenesis of splenic marginal zone lymphoma are poorly understood. The lymphoma lacks chromosome translocation, and approximately 30% of cases are featured by 7q deletion, but the gene targeted by the deletion is unknown.
Qingguo Yan, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski, Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval, Andrew Wotherspoon, Ming-Qing Du   +9 more
doaj   +1 more source

Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects

Journal of Cell Communication and Signaling, Volume 20, Issue 1, March 2026.
Abstract MALT1, a multifunctional protease molecule, plays a pivotal role in the adaptive immunity by regulating immune cell survival, proliferation and activation through the nuclear transcription factor‐κB (NF‐κB) signaling pathway by scaffold and protease activities.
Xintao Cao, Peixia Wang, Yuan Ji, Yongliang Sun, Dejiu Zhang   +4 more
wiley   +1 more source

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara, Bertorelle, Roberta, Facco, Monica, Frezzato, Federica, Imbergamo, Silvia, Piazza, Francesco, Piva, Elisa, Pizzi, Marco, Riva, Marcello, Scomazzon, Edoardo, Semenzato, Gianpietro, Trentin, Livio, Visentin, Andrea   +12 more
core   +1 more source

Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab

Cancer, Volume 132, Issue 5, 1 March 2026.
Abstract Background Bendamustine‐rituximab (BR) is common frontline therapy for indolent B‐cell non‐Hodgkin lymphomas (iBCL), but its association with secondary primary malignancies (SPM) is unclear. Methods The authors conducted a population‐based study using linked Ontario health care databases. Patients ≥18 years old with untreated iBCL receiving BR
Gwynivere A. Davies, Anca Prica, Zharmaine Ante, Ning Liu, Gregory R. Pond, Amaris K. Balitsky, Adam Suleman, Lee Mozessohn   +7 more
wiley   +1 more source